Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.
about
Epigenetics advancing personalized nanomedicine in cancer therapyInsulinotropic effect of the non-steroidal compound STX in pancreatic β-cellsGenetics of type 2 diabetes: insights into the pathogenesis and its clinical application.Pharmacogenetics in type 2 diabetes: potential implications for clinical practiceThe success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era.Gene-environment and gene-treatment interactions in type 2 diabetes: progress, pitfalls, and prospectsGlucose Tolerance, MTHFR C677T and NOS3 G894T Polymorphisms, and Global DNA Methylation in Mixed Ancestry African Individuals.Introduction to personalized medicine in diabetes mellitus.The pharmacogenetics of type 2 diabetes: a systematic review.Expression quantitative trait analyses to identify causal genetic variants for type 2 diabetes susceptibility.Potential of pluripotent stem cells for diabetes therapy.CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Personalized medicine and type 2 diabetes: lesson from epigenetics.Epigenetics in the development, modification, and prevention of cardiovascular disease.The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia.Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.Allele and genotype frequency of a genetic variant in ataxia telangiectasia mutated gene affecting glycemic response to metformin in South Indian population.Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study.Meta-analysis of association between TCF7L2 polymorphism rs7903146 and type 2 diabetes mellitus.Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
P2860
Q27010637-CE4EADFD-ED8A-444D-B080-7365BB028199Q28482218-56127A81-D16B-4D2F-AFC6-1F148224AE32Q33593963-5F614122-D235-48D1-80B0-423B713B37BAQ35840645-30410330-6822-412E-BBF0-C7F523C758E3Q36203536-BCFEAEE8-63F8-439B-9DFE-74B363A7DFC1Q36782845-9865B77E-591E-4E05-B3EF-A50949192E45Q37470876-808FD9B0-40F0-474D-937D-0445D4E0CF15Q37523745-7FA01850-8177-4AC0-821F-DBB5C84ABDD0Q37597017-9A6EB2AE-4C7F-433E-975F-475E02065EC6Q37708629-0EA03CB3-C087-407F-875B-94C8B0060090Q38023290-314A9CAC-90F4-47A6-889A-6AFB8EF70801Q38059889-772F0681-0A46-432F-818F-55127985505EQ38110432-4F51E73D-99A0-4DCA-95D6-D758A761C60BQ38210476-4F60D5E7-A22B-433B-A94E-3F3E49E4AF92Q38247712-CE6F6CA3-1252-4883-A1C6-85E6C6C51BC4Q39123582-2AE35B47-8A9E-4C1A-A32D-26E52065BF40Q39154772-F1F8ECF8-7136-4273-80E1-15134DB1055BQ39467511-EC19887B-897F-4430-8F32-FA90E0CE1E86Q40858276-523433F9-0758-4F1D-87FD-5FF904179854Q42786983-A7235768-02E7-49C2-B70A-DC1EAA198B8DQ47570862-41A57040-6410-46EB-9F8B-EB2E20B85191Q47911043-0C2AC8DE-A3D6-4527-BE09-C2CF49E8073AQ50035868-AD74F5AB-9A2E-466B-B6EF-59A0C5A3C9C6Q51556981-B35B007D-90EA-4514-89E0-75809F4E31CBQ54235357-4EA9BBE4-3D33-430E-BA1D-DEE26BC9F0E6
P2860
Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacogenomics of oral antid ...... harmacoepigenomic perspective.
@ast
Pharmacogenomics of oral antid ...... harmacoepigenomic perspective.
@en
type
label
Pharmacogenomics of oral antid ...... harmacoepigenomic perspective.
@ast
Pharmacogenomics of oral antid ...... harmacoepigenomic perspective.
@en
prefLabel
Pharmacogenomics of oral antid ...... harmacoepigenomic perspective.
@ast
Pharmacogenomics of oral antid ...... harmacoepigenomic perspective.
@en
P2860
P356
P1433
P1476
Pharmacogenomics of oral antid ...... harmacoepigenomic perspective.
@en
P2093
Anna Tavridou
Vangelis G Manolopoulos
P2860
P304
P356
10.2217/PGS.11.65
P577
2011-08-01T00:00:00Z